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4. Introduction 
During the last three decades there has been extraordinary progress in the understanding of 
the pathogenesis, and most importantly, the treatment of ischemic heart disease. This has 
resulted in impressive improvements in survival for patients hospitalised with acute 
myocardial infarction. However, in this era of myocardial reperfusion, cardiogenic shock is 
still the leading cause of death for patients hospitalised with acute myocardial infarction. 
Mortality rates for patients in cardiogenic shock are still exceedingly high, demonstrating the 
limitations of early and aggressive revascularization. Moreover, there is a growing epidemic 
of patients with chronic heart failure and increasing numbers of patients with acute-on-
chronic heart failure necessitating hospitalisation. Of concern amidst the general 
improvements, however, the most recent clinical trials have all failed to improve outcomes for 
patients with acute heart failure, and new insights into the underlying pathophysiology and 
therapy for these syndromes are needed. The present work was initiated to describe the 
clinical epidemiology of acute heart failure; i.e. incidence, treatments employed and outcome. 
Also, to improve the pathophysiological understanding of the acute heart failure syndromes, 
we have done a number of exploratory assessments of the integrated inflammatory and 
vascular responses in patients with the most severe form of acute heart failure, namely 




5.1 Acute heart failure 
The European Society of Cardiology (ESC) published in 2005 the first set of guidelines on the 
diagnosis and treatment of acute heart failure.6 The definition of acute heart failure used in 
these guidelines was: 
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“The rapid onset of symptoms and signs secondary to abnormal cardiac function. The cardiac 
dysfunction can be related to systolic or diastolic dysfunction, to abnormalities in cardiac 
rhythm, or to pre-load and after-load mismatch. It is often life threatening and requires 
urgent treatment” 
 
ESC further divided AHF into a set of six distinct clinical conditions: 1) Acute 
decompensated heart failure, 2) Hypertensive acute heart failure, 3) Pulmonary edema, 4) 
Cardiogenic shock, 5) High output failure, 6) Right heart failure.  
The broad spectrum and heterogeneity of different AHF conditions are apparent from 
this classification. There is a great span from patients with acute decompensated heart failure, 
which by definition present with mild AHF symptoms, to cardiogenic shock with regards to 
clinical presentation, prognosis and treatment.   
 
5.2 Epidemiology of acute heart failure 
There have been several publications aiming to describe the AHF population, including the 
major EuroHeart Failure Survey II (EHFS II) and the US Acute Decompensated Heart Failure 
National Registry (ADHERE).7-12 The EuroHeart Failure Survey II included 3580 patients 
with AHF hospitalized in 133 European hospitals from 2004-2005. The aim was to give a 
description based on the European Society of Cardiology (ESC) guidelines on the diagnosis 
and treatment of AHF.12 The overwhelming majority of patients had mild forms of AHF and 
the main precipitating factors for AHF were acute coronary syndromes (30 %), arrhytmias (32 
%) and valvular pathology (27 %). AHF patients were typically elderly (mean age 69.9 years) 
and more than two-thirds had a prior history of heart failure. Pre-existing medical conditions 
were abundant, such as coronary heart disease (54 %), hypertension (63 %), atrial 
fibrillation/flutter (39 %), valvular disease (34 %) and diabetes mellitus (33 %). The overall 
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in-hospital mortality was 6.7 % in EHFS-II.  Other surveys on AHF report varying mortality 
rates:  ADHERE (4.0 %)10, Italian AHF survey (7.3 %)9 and ALARM-HF (12 %)8. Although 
the in-hospital mortality in mild forms of AHF is modest, an episode of AHF requiring 
hospital treatment is associated with a dismal intermediate and long term prognosis and as 
such identifies patients at increased risk.13 
 The in-hospital prognosis of patients requiring treatment at the ICU and CCU is, 
however, worse. The French EFICA study “Etude Francaise l’Innsuficiens Cardiaque Aigue” 
found in this more acutely ill AHF population an overall four week mortality of 27 %. The 
international Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) 
confirmed this finding with an in-hospital mortality rate of 18 % and 11 % for ICU and CCU 
treated patients, respectively.8 
 
Epidemiology of cardiogenic shock 
The most severe form of AHF, cardiogenic shock, stands out with excessively high short term 
mortality. The hospital mortality rates for these patients, regardless of cause, have been 
reported in the most recent surveys to lie just below 50 %12, 14-16 and the vast majority of 
deaths are cardiac17. ACS was the predominant etiology (72 %), while valvular dysfunction 
was a precipitating factor in 17 % in EHFS-II. Compared to the general AHF population, CS 
patients were slightly younger (mean age 67 years) and predominantly males (68 %). The 
majority had no prior history of heart failure (65 %), but the frequency of underlying medical 
conditions was largely similar to other AHF conditions. The overall incidence of CS in this 
survey was 4 %. The incidence of CS following ACS in larger registries is reported to lie 
between 8-9 % for STEMI14, 16, 18 and 2-3 % for non-STEMI ACS14, 19, 20. Although reports 
are conflicting, the incidence and in-hospital mortality of CS following AMI seems to be 
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declining.14, 19, 21 Importantly, long term follow-up have established that patients who survive 
hospitalisation have a relatively good long term survival and also quality of life.22, 23  
 
Epidemiology of postcardiotomy heart failure 
Acute heart failure following open heart surgery is virtually not mentioned in the current AHF 
guidelines and large registries. However, this entity shares a number of common 
epidemiological and pathophysiological aspects with acute heart failure of non-surgical 
etiology. Predictors for developing postcardiotomy HF include low preoperative left 
ventricular ejection fraction, repeat surgery, emergency operation, female gender and high 
age.24 Depending on the definition used, postcardiotomy HF is reported to occur in 2 -9 % of 
all open heart operations with mortality rates ranging from 17 – 34 %.24-26  There is, however, 
a great spectrum of patients within this group ranging from patients presenting with mild AHF 
syndromes to patients presenting with postcardiotomy shock refractory to conventional 
treatments. In this latter group, in-hospital mortality rates as high as 80 % was observed in 
patients requiring multiple high doses of inotropic drugs.27 In the current registries and patient 
series the overall percentage of open heart surgical procedures necessitating ventricular assist 
systems for circulatory support was 0.2-1.2 %.27-33  The reported outcomes for these patients 
are highly variable with survival rates to discharge ranging from 25-60 %.27-33 However, the 
largest report to date from the US “Society of Thoracic Surgeons` National Cardiac Database” 
demonstrated significantly improved survival rates for these patients from 1995 through 
2004.30 In this report mean age was 63 years, predominately male patients and most patients 




5.3 Pathophysiology and definitions of cardiogenic shock and postcardiotomy heart 
failure 
Cardiogenic shock is characterized by a failure of the heart to deliver a sufficient cardiac 
output to maintain adequate perfusion of vital organs with subsequent inadequate cellular 
metabolism. Irreversible cell damage and organ failure are the consequences. The basic 
clinical diagnosis of this condition is typically based on the presentation of arterial 
hypotension and signs of reduced tissue perfusion. Impaired perfusion of the kidney, brain 
and skin result in oliguria, altered mental status accompanied by cold and clammy skin. The 
ESC guidelines on acute heart failure suggested the following definition6: 
 
“Cardiogenic shock is defined as evidence of tissue hypoperfusion induced by heart 
failure after correction of pre-load.  It is usually characterized by reduced blood 
pressure (systolic BP < 90 mmHg or a drop of mean arterial pressure > 30 mmHg) 
and/or low urine output (<0.5 ml/kg/h), with a pulse rate > 60 b.p.m with or without 
evidence of organ congestion. There is a continuum from low cardiac output syndrome 
to cardiogenic shock” 
 
A similar, but more exact definition with regards to hemodynamic variables was used for 
inclusion of patients in the seminal trial Should We Emergently Revascularize Occluded 
Coronaries for Cardiogenic Shock (SHOCK).34 This definition is often referred to in recent 
publications concerning patients with cardiogenic shock: 
 
“The clinical criteria were hypotension (a systolic blood pressure of < 90 mmHg for 
at least 30 minutes or the need for supportive measures to maintain a systolic blood 
pressure of  >= 90 mmHg) and end-organ hypoperfusion (cool extremities or a urine 
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output of < 30 ml per hour, and a heart rate >= 60 beats per minute). The 
hemodynamic criteria were a cardiac index of no more than 2.2 L/m2 and a 
pulmonary-capillary wedge pressure of at least 15 mmHg”   
  
 The definition of CS is complicated by the wide array of support measures initiated early to 
improve hemodynamics and maintaining organ function in these patients. Thus, objective 
hemodynamic assessment and clinical findings sometimes reflects medically and 
mechanically supported patients that most likely would succumb without support. This 
explains some of the variability in the definitions of cardiogenic shock used in registries and 
clinical trials, but also complicates the diagnosis and treatment of these patients in clinical 
practice.   
 Postcardiotomy HF is usually defined as inadequate cardiac performance following 
heart surgery requiring inotropic and/or intra-aortic balloon counterpulsation support.24 
However, the definitions used vary and the general definitions of AHF syndromes may also 
be applicable to describe heart failure following surgery. Of importance, right ventricular 
dysfunction is present in up to 40 % of post surgical patients who develop shock and is 
associated with high mortality.35 Of importance, a large proportion of patients with shock 
following open-heart surgery are in a state of vasodilatory shock with a relatively preserved 
cardiac function.36 
 While invasive hemodynamic parameters obtained by right heart catheterization 
(Swan-Ganz catheter) represent a gold standard to ensure a correct diagnosis, evaluation with 
echocardiography has reduced the need for invasive measures. Invasive and 
echocardiographic hemodynamic indicators provide important information about cardiac 
function and central blood flow. Importantly, short term outcome is directly related to the 
severity of hemodynamic derangement.37, 38 This is also the case for revascularized patients.38 
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Prognosis is also associated with the initial left ventricular systolic function and severity of 
mitral regurgitation as assessed by echocardiogrphy39 Hemodynamic measurements do not, 
however, provide evidence of end-organ hypoperfusion, the hallmark of shock. Besides the 
mentioned clinical signs of hypoperfusion, the diagnosis can be supported by increased lactate 
and lactacidosis as a result of tissue hypoxia and anaerobic metabolism. Hyperlactatemia is a 
sign of profound and persisting shock and provides prognostic information on the patient.40 
Also, the mixed venous oxygen saturation is typically reduced in low output shock and 
reflects an imbalance between oxygen delivery and uptake.    
In the SHOCK Trial registry including patients with cardiogenic shock after acute 
myocardial infarction, predominant left ventricular failure was seen in 79 %, isolated right 
ventricular failure in 3 %, severe mitral regurgitation in 7 %, ventricular septal rupture in 4 % 
and tamponade in 1.4 %.41 
The classical cardiogenic shock occurs after a massive and extensive myocardial 
infarction with a loss of ventricular mass > 40 % leading to severe left ventricular 
dysfunction, pump failure and subsequently reduced cardiac output and blood pressure.42-44 
The compensatory neurohormonal responses lead to vasoconstriction, tachycardia and fluid 
retention which in turn can lead to a progressive worsening of coronary blood flow and 
myocardial function. This classical description of cardiogenic shock does not necessarily 
correspond with today’s patients. Today’s patients are often revascularized by means of PCI 
or CABG, mechanically ventilated, they are old (mean age 67 years EHFS-II) and have 
multiple comorbideties including pre-existing heart failure. Also, many of the patients 
receiving full invasive treatment today would not be considered for treatment even a few 
decades ago. Importantly, observations from the SHOCK trial and registry demonstrated a 
wide variation in left ventricular ejection fraction (average 30 %) and systemic vascular 
resistance in patients with shock suggesting that the pathophysiological mechanisms of 
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cardiogenic shock may vary and not be explained fully by traditional models.45 Also, the 
average systemic vascular resistance (SVR) was not elevated and one-fifth of the patients 
showed clinical signs of severe systemic inflammation with reduced SVR.46, 47 On the other 
side of the spectrum, a subset of patients also show signs of hypoperfusion following AMI 
with elevated SVR and without hypotension.47   
 The notion that a number of patients with CS presented with signs of systemic 
inflammation and that systemic vascular resistance was inappropriately low leads to a new 
hypothesis; that the inflammatory response through induction of excessive NO production 
inhibited compensatory vasoconstriction and impaired myocardial function contributing to 
persistence of shock.45  
 
Treatment refractory cardiogenic shock 
Profound shock at presentation or refractory and persistent cardiogenic shock despite patent 
revascularization, IABP and inotropes/vasopressors, is a subgroup of patients overrepresented 
among the fatalities. Sheu et. al found CS patients in profund shock despite inotropic and 
IABP support before PCI to have a substantially higher mortality (71 % vs 22 %).48 Similar 
high mortality rates were found in non-responders to vasopressors after PCI (68 % vs 20 %)49 
and patients with the highest vasopressor needs had an excessively high mortality (86 %)50. A 
high need for vasopressors was also predictive of poor outcome in patients from the Triumph 
trial with persistent CS after successful revascularization.51   
As discussed above, a significant subset of CS patients does not have an effective 
vasoconstriction with increased systemic vascular resistance despite vasopressor therapy. A 
vasodilatory shock with poor response to vasopressors can occur secondary to any type of 
severe and long lasting shock.52 This inappropriate vasodilatation is also evident in patients 
following cardiopulmonary bypass or treatment with ventricular assist devices.36 There are 
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several proposed mechanisms behind the vasodilation in vasodilatory shock, including 
unregulated (increased) NO synthesis, deficiency of vasopressin secretion and lactic acidosis 
causing vascular smooth muscle dilation.52  
 
5.4 Invasive treatments for acute heart failure. 
 
Revascularization 
Acute coronary syndromes were a precipitating factor for AHF in one-third of all patients in 
the EHFS-II registry.12 This was even more frequent in patients who presented with 
pulmonary edema (49 %) and cardiogenic shock (72 %). Half of the patients with CS 
presented with STEMI, while non-STEMI were mostly found in patients with pulmonary 
edema. Existing guidelines advocate an early invasive revascularization strategy for patients 
with CS.6, 53-55 A reported invasive revascularization frequency in EHFS-II around two-thirds 
of patients with CS secondary to ACS, indicates a restrictive utilization of invasive 
revascularization compared to existing guidelines.12 Of even more concern, in the “Global 
Registry of Acute Coronary Events” (GRACE) and “Euro Heart Survey of Acute Coronary 
Events” (EHS ACS 1), a 40 - 43 % revascularization rate for AMI complicated with CS was 
observed.56, 57 
Previous registry reports have demonstrated that early invasive revascularization is 
beneficial even in clinically selected elderly patients, but this has not been confirmed in 
randomized trials.16, 56, 58 The ACC/AHA guidelines give a class IIa recommendation for early 
revascularization in selected elderly patients with STEMI 59, but clear evidence guiding the 
choice of revascularization strategy in non-STEMI presenting with CS, is lacking 60. 
The role of CABG in the acute phase of STEMI and CS is somewhat unclear, but the 
AHA/ACC guidelines state that CABG should be used if there is a suitable anatomy (main 
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stem, three vessel disease) and if PCI fails to adequately reperfuse the myocardium or cannot 
be done.59, 61 Importantly, approximately 40 % of the patients revascularized early in the 
SHOCK trial were treated with CABG with no higher mortality than patients treated by PCI. 
62 There are, however, no robust data comparing PCI and CABG in the setting of CS, but the 
two interventions seem to be comparable in high risk populations.63 By attacking the culprit 
lesions only, there is a risk of inadequate revascularization in some of these patients.64, 65 
Potentially, the rather disappointing effects of revascularization could be improved by 
allocating more patients to early complete revascularization by CABG, as the majority of CS 
patients present with multi vessel disease.62    
Less severe forms of acute heart failure have received much less attention than CS in 
regard to invasive revascularization. Data from the NRMI registry revealed an in-hospital 
mortality rate of 24 % for this group and invasive revascularization was performed in 20 – 36 
% of the patients depending on timing of HF onset.66 Similar revascularization rates were 
reported from the GRACE registry in patients with ACS complicated with HF.67 
 
Valvular surgery 
The rate of severe mitral regurgitation was 12.4 % in the mixed population of patients with 
cardiogenic shock in EHFS-II, considerably higher than reported from the SHOCK trial 
registry (7 %).12, 41 Close to half of the patients with severe MR received valvular surgery in 
the SHOCK trial registry and these patients had improved unadjusted survival rates compared 
to conservatively treated patients.68 The proportion of these patients in which mitral 
regurgitation was functional, or secondary to left ventricular dysfunction, was not reported. 
To what extent valve surgery should be performed in the setting of ischemic functional MR 
and cardiogenic shock, is not known, as revascularization alone can improve cardiac function 
in these patients. Also, medical stabilisation and IABP support can improve the situation. 
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Surgical repair can, however, be the only option when conservative treatment fails. For 
patients presenting with severe aortic regurgitation or aortic stenosis in the setting of 
cardiogenic shock, the prognosis is particularly bad, and urgent operative valve replacement 
usually represents the only option for appropriate candidates for surgery.(Katz JN (2009), 
Valvular heart disease in cardiogenic shock, In J. S. Hochman & E. M. Ohman (Eds.), 
Cardiogenic shock. Wiley-Blackwell) 
 
Intra-aortic balloon counterpulsation 
Despite being a recommended therapy in CS, only 39 % and 18 % in the NRMI registry and 
EHS ACS 1, respectively, received treatment with IABP.6, 16, 53, 57, 59 A potential under-
utilization of mechanical assistance was also found in EHFS-II where only one-third of 
patients with CS received such therapy compared to half of the patients in the SHOCK trial 
registry.41 
 
5.5 Limitations to the conventional invasive treatments 
Although the aggressive use of early invasive revascularization and IABP has been found to 
improve long term survival in patients with cardiogenic shock following AMI, the high early 
mortality in the group is not convincingly reduced.34 This is a critical shortcoming in the 
current standard treatment for these patients as the majority of cardiac deaths occur within the 
first 1-2 days.17 Additional mechanical circulatory support by means of a ventricular assist 
device (VAD) represents the only option to ensure survival for some of these patients. VADs 
are usually applied in refractory circulatory shock when maximal conventional medical and 
invasive treatments, including the use of IABP, fail to restore the circulation. In this subgroup 
of patients mortality is exceedingly high, justifying the use of treatment modalities associated 
with potentially fatal complications and high costs. The reported mortality rates from different 
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patient series treated with VAD after AMI lies between 30-80 % and can represent enhanced 
survival for these patients.48, 69-78 In the setting of AHF, temporary treatment with VADs can 
serve as a bridge to recovery, long term assist systems or transplantation. It can also facilitate 
and provide time for patients with the most severely compromised circulation (i.e. cardiac 
arrest) to undergo necessary revascularization and/or cardiac surgery.48, 73, 79 
 Current guidelines on acute heart failure give a class IIa recommendation for the use 
of such devices.6, 55 The robust evidence guiding such treatment is, however, scarce, and not 
supported by randomized trials. 
 
5.6 The endothelial function during severe acute heart failure 
 
 
5.6.1 The endothelium and endothelial function in cardiovascular disease. 
A healthy vascular endothelium is an active metabolic and endocrine organ with key functions 
in maintaining vascular homeostasis. It regulates vessel tone by a balanced production of 
vasodilators (nitric oxide, prostacyclin) and vasoconstrictors (endothelin, thromboxane A2). It 
also plays an active role in the equilibrium of hemostasis and fibrinolysis and produce 
cytokines and adhesion molecules and participate actively in the inflammatory response.80 
Alteration of normal endothelial physiology through an imbalance between vasodilators and 
vasoconstrictors constitute endothelial dysfunction.81 Reduced bioavailability of vasodilators, 
and NO in particular, accounts for the decreased endothelial dependent vascular relaxation – a 
hallmark of endothelial dysfunction.  
Endothelial dysfunction is a systemic process occurring throughout the vasculature 
and results in abnormal regulation of blood vessel tone and thus regulation of flow and the 
loss of the atheroprotective properties of the endothelium. Thus, it is viewed a prerequisite for 
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atherogenesis and development of clinical cardiovascular disease82. Importantly, endothelial 
dysfunction is shown to be predictive of future cardiovascular events83, 84.  
 
5.6.2 Endothelial function in acute disease states – role of inflammation? 
A functional endothelium and nitric oxide bioavailability are essential for maintenance and 
regulation of blood flow and tissue perfusion. Thus both micro and macrovascular endothelial 
dysfunction are likely to be key contributors to organ failure in critical disease and sepsis in 
particular.85 The role of the endothelium and the significance of endothelial dysfunction 
during acute disease are not much studied with regards to cardiovascular disease, including 
acute heart failure.  A few clinical studies have assessed vascular reactivity in shock and 
critical illness, demonstrating an impaired vascular response during reactive hyperemia. 
Kirschenbaum et al. found an attenuated increase in forearm blood flow during reactive 
hyperemia in patients with CS and septic shock compared with healthy controls.86 This 
finding has been confirmed by measuring microvascular reactivity in both sepsis and septic 
shock.87, 88  
Serum from patients with severe heart failure down regulates eNOS and induces 
apoptosis in endothelial cells, an effect partly caused by TNF-α.89 During severe 
decompensation of chronic heart failure it has also been demonstrated that vascular 
endothelial cells are activated with signs of increased cellular oxidative stress and expression 
of COX-II and iNOS.90 A transitory impairment of endothelial function after exposure to 
cytokines and transitory inflammation has been described in an experimental setting.91-97 
Animal studies have also suggested that TNF-α induce coronary endothelial dysfunction 
following ischemia/reperfusion injury.98 This transient effect of inflammation on endothelial 
function has by some investigators been termed “endothelial stunning”.97 Furthermore, TNF-α 
and IL-6 have also been shown to induce endothelium dependent vasoconstriction in human 
arterial segments and thus the potential predisposition to vasospasm and vessel occlusion.99  
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 Both patients with advanced chronic heart failure and acute hear failure have been 
shown to have elevated circulating levels of inflammatory cytokines100-103,  and TNF-α was 
related to impaired flow mediated dilation in patients with chronic heart failure104-106. 
Furthermore, experimentally induced heart failure in dogs caused coronary endothelial 
dysfunction and reduced the aortic expression of eNOS and COX-I.107 Importantly, treatment 
with a TNF-α antagonist improved endothelial function in patients with advanced heart failure 
correlating with a reduction in TNF-α levels, providing a mechanistic link between 
inflammation and systemic endothelial function.108 However, large scale clinical trials have 
failed to show any clinically relevant benefit from anti-inflammatory treatment in 
cardiovascular disease including heart failure patients.109-114   
There is evidence that acute systemic inflammation is related to transient increase in 
the risk of cardiovascular events.115 Interestingly, Tonetti et al. could demonstrate in a 
randomized trial that intensive treatment of chronic periodontitis resulted in an acute and 
transient systemic inflammation accompanied by endothelial dysfunction that resolved with 
improved endothelial function compared to baseline after 6 months.116 It has been 
hypothesized that acute endothelial dysfunction might be the mechanism linking 
inflammation to acute cardiovascular events.117 
While most studies focus primarily on the risk for vascular disturbances and 
cardiovascular events secondary to infection and inflammation, there is increasing awareness 
on the importance of inflammation and clinically evident SIRS during severe acute 
cardiovascular diseases such as acute MI and CS.45, 46, 50, 118-123  Furthermore, elevated levels 
of inflammatory cytokines are associated with increased mortality in CS and acute MI.50, 120, 
121 The significance and relation of the observed inflammatory response and vascular 
disturbances in acute cardiovascular disease is, however, unknown. 
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5.6.3 Role of nitric oxide and endogenous NO inhibition in acute heart failure  
Nitric oxide is one of the major endothelium derived vasoactive mediators. The amino acid L-
arginin is the substrate for NO synthase (NOS) and thus precursor for formation of nitric 
oxide (NO). Three isoforms of NOS have been indentified; nNOS (NOS I), iNOS (NOS II) 
and eNOS (NOS III). Endothelium derived NO produced under basal conditions is stimulated 
by several receptor agonists and also shear stress induced by blood flow. It is detrimental for 
vascular homeostasis by regulating vascular tone and blood flow, but acts vasoprotective by 
inhibiting platelet aggregation, leukocyte adhesion and smooth muscle proliferation.124 
Widespread induction of the inducible form of NOS (iNOS) can be harmful as it leads to 
vasodilation and hyporeactivity to vasoconstrictors.52 It may also cause myocardial 
dysfunction especially in conditions with concurrent oxidative stress.125 In addition, the 
formation of reactive nitrogen species (peroxynitrite) can be detrimental for endothelial 
cells.126 However, iNOS can have both deleterious and beneficial effects in circulatory shock 
states and its role in the observed myocardial and vascular abnormalities in CS is still 
undefined.125 
The recently published Triumph trial illustrated this complex role of NO in severe 
heart failure.127 This trial addressed the possible adverse effects of a presumed excessive nitric 
oxide production (by iNOS) secondary to inflammation in CS. In this study, treatment with an 
unselective NO inhibitor in patients with persisting shock failed to reduce the duration of 
shock and mortality. NO is a principal mediator for refractory hypotension in septic shock52, 
125, but clinical studies using unselective NO inhibitors in sepsis also revealed deleterious 
effects on organ function and most importantly increased mortality despite positive effects on 





Asymmetrical dimethylarginine (ADMA) is a naturally occurring competitive inhibitor of all 
three forms of nitric oxide synthase.130 There are several studies suggesting that ADMA is a 
reliable marker of increased cardiovascular risk. Elevated levels of ADMA have been 
reported in cardiovascular conditions such as peripheral occlusive arterial disease, stable and 
unstable coronary artery disease and chronic heart failure.131  A variety of conditions 
associated with increased cardiovascular risk such as hypercholesterolemia, hypertension, 
diabetes mellitus and chronic renal failure have also been reported to have elevated ADMA 
levels.131  Importantly, elevated ADMA seems to identify individuals at increased risk for 
future cardiac events.132-134 Furthermore, ADMA is also implicated in the pathogenesis and 
development of endothelial dysfunction.130, 135-137  
ADMA is formed by methylation of arginine residues of proteins by the action of the 
enzymes protein arginine methyltransferases (PRMTs) which results in asymmetric 
dimethylarginine (ADMA), monomethyl arginine (l-NMMA) and symmetric 
dimethylarginine (SDMA).138 A subsequent proteolysis of these methylated arginine residues 
results in free intracellular ADMA that can be transported out of cells by cationic amino acid 
transporters(CAT).139 The intracellular concentration of ADMA in endothelial cells is 
believed to be more than 10-fold higher than circulating levels.131, 140  Main routes of 
elimination are metabolic degradation by dimethylarginine dimethylaminohydrolase (DDAH) 
in the liver and kidney and to a lesser extent by renal excretion.139, 141 Accumulation of 
ADMA is though to occur mainly secondary to inhibition and dysregulation of DDAH.139 
DDAH is sensitive to oxidative and nitrosative stress and thus pathogenic stimuli such as 
inflammation that may lower DDAH activity leading to intracellular ADMA accumulation.139, 
142, 143 Importantly, experimental studies have demonstrated that loss of DDAH activity cause 
accumulation of ADMA and disruption of NO signalling with subsequent endothelial 
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dysfunction and increased systemic vascular resistance.137 However, in vitro stimulation of rat 
vascular smooth muscle cells with IL-1β up-regulated both iNOS and DDAH144 and reduced 
levels of circulating ADMA has been described after experimental endotoxemia and at the 
onset of acute infection93, 145. Of note, the relative contribution of degradation by DDAH and 
cellular export and import of both L-arginine and ADMA by CAT may vary in different 
conditions, and thereby affect the intracellular NOS substrate:inhibitor ratio.140    
 In contrast to its increasing recognition as a risk marker in chronic cardiovascular 
disease, little is known about ADMA’s role with regards to acute vascular disturbances in 
acutely ill patients and acute heart failure in particular. In a relatively large cohort (SHOCK-II 
trial) of patients with cardiogenic shock following acute myocardial infarction, ADMA was 
an independent predictor of increased mortality and also associated with increased pulmonary 
capillary wedge pressure and systolic pulmonary artery pressure.146 Experimental studies have 
demonstrated adverse hemodynamic effects after systemic administration of ADMA in 
healthy humans with reduced heart rate and cardiac output and increased blood pressure and 
systemic vascular resistance. Furthermore, ADMA impaired the physiologic increase in 
cardiac output following exercise.141 Experimental studies have also shown that induction of 
heart failure in animals lead to increased ADMA levels.136, 147 In addition, ADMA levels were 
elevated in patients with chronic heart failure and seemed to further increase in patients with 
acute decompensation.148, 149  However, a recent study on acute heart failure patients failed to 
confirm these findings, and ADMA also did not seem to identify patients with increased risk 
for future cardiac events including episodes of decompensation.150 
Vascular and endothelial dysfunction are key components in the development of organ 
failure and death in critically ill patients. ADMA was an independent predictor for poor 
outcome and correlated with organ failure in a mixed population of critically ill patients.151 
Also, in septic patients ADMA levels seem to be associated with short term mortality and the 
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degree of organ dysfunction.88, 152, 153 The ratio between L-arginine as a substrate for NO-
synthesis and ADMA was reduced in sepsis with the lowest L-arginin/ADMA ratio found in 
patients with shock.88 Increasing ADMA levels were associated with worsening 
microvascular reactivity. It has been hypothesized that accumulation of ADMA plays a causal 
role in the development of organ failure by blocking NO production and thereby reducing 
organ perfusion.154 However, others have proposed that accumulation of ADMA secondary to 
DDAH inhibition is a counter regulatory mechanism to limit excessive NO production in 
sepsis.155  
 
5.7 Circulating endothelial progenitor cells for vascular repair in cardiovascular disease 
In 1997 Asahara et al. reported on the existence of circulating bone marrow derived cells that 
differentiated in vitro into cell with endothelial characteristics. They termed these cells 
endothelial progenitor cells (EPCs).156 The potential role for EPCs in preserving a healthy 
endothelium was further demonstrated by Hill et al. who found a strong correlation between 
the numbers of colony forming circulating EPCs and conventional cardiovascular risk factors 
and endothelial function (FMD).157 A number of studies have demonstrated impaired numbers 
and function of circulating EPCs in patients with manifest cardiovascular disease158, 159, but 
also in conditions associated with increased cardiovascular risk such as diabetes mellitus160-
162, hypercholesterolemia163, cigarette smoking164 and chronic renal failure165. Also, the 
numbers of circulating EPCs have been shown to predict future cardiovascular events.166, 167 
  Importantly, these cells have been shown to replenish damaged endothelium and 
enhance adult neovascularization at sites of ischemia in experimental models.156, 168-176 Based 
on these observations it has been assumed that the bone marrow and circulation contains a 
pool of bone marrow derived endothelial progenitors maintaining vascular homeostasis. 
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5.7.1 Defining endothelial progenitor cells  
Endothelial progenitor cells represent a small subpopulation of peripheral blood mononuclear 
cells (MNC). Since the first description of EPCs, different techniques for isolation and culture 
have yielded at least three different putative EPC populations derived from peripheral 
blood.157, 177-180 EPCs are most commonly divided into early outgrowth and late outgrowth 
EPCs with different morphology, functional properties and growth potential. The late 
outgrowth EPCs differ from early outgrowth EPCs in having a high proliferative capacity and 
that they do not express the hematopoetic markers CD14 and CD45.177, 181, 182 It has thus been 
argued that early outgrowth EPCs consists of myeloid cells of hematopoietic origin.177, 183  
Studies also indicate that early EPCs have a limited degree of engraftment and incorporation 
into new vessels and it has been proposed that they facilitate vascular regeneration mainly 
through secretion of proangiogenic factors.178, 183-186 Late outgrowth EPCs seem to have 
favourable in vitro angiogenic properties compared to other putative EPCs.187 Importantly, 
they have also been demonstrated to form de novo vessels in vivo.182, 188-190 These studies 
indicate that late outgrowth EPCs are the true progenitors of mature endothelial cells. 
However, no studies have so far been performed in humans using this specific cell population. 
 
5.7.2 Therapeutic stem and progenitor cell transplantation  
Bone marrow derived stem and progenitor cell transplantation have showed promising effects 
on reducing infarct size and improving cardiac function in experimental models.172-174, 191 
Despite a modest but beneficial effect on cardiac function and remodelling following cell 
therapy in clinical trials192-194, the potent effects observed in experimental models have 
however not been convincingly reproduced in clinical trials so far. The utility of stem and 
progenitor cell transplantation is potentially hampered by their low numbers in the circulation, 
impaired functional activity, induction of unfavourable functional changes during culture and 
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by inhibitory factors in the recipient causing reduced cell survival and poor engraftment of the 
transplanted cells.158, 195-197 Proposed strategies to improve engraftment of transplanted EPCs 
and bone marrow derived cells include concomitant infusion of proangiogenic cytokines such 
as VEGF and SDF-1198, 199, but also by priming cells prior to transplantation200, 201. A novel 
candidate to improve the utility of EPC transplantation is the endogenous vasoactive peptide 
Adrenomedullin (AM). It is synthesized in most tissues including endothelial cells and has a 
variety of biological actions suggesting a protective effect against vascular damage and 
progression of atherosclerosis.202 The endothelial effects include inhibition of endothelial 
apoptosis203 and promotion of endothelial proliferation204, 205. Similar beneficial effects of AM 
have also been demonstrated on early outgrowth EPCs.206, 207 Of importance, AM has been 
shown to promote angiogenesis in various experimental models including coadministration 
with bone marrow derived cells in ischemia.206, 208-211  
 
6. Aims of the studies 
 
6.1 Paper I 
At the time of planning and initiation of this retrospective study on patients with AHF 
admitted to the ICU/CCU at the University Hospital of North Norway there were no prior 
studies describing the overall population of patients with acute heart failure necessitating 
treatment and surveillance at the ICU/CCU. Of interest, patients with acute heart failure after 
cardiac surgery, i.e. postcardiotomy HF, have still not been mentioned in the subsequently 
reported large registries (EHFS II, EFICA, ADHERE).  
  In this study we give an overview and description of all patients admitted to the 
ICU/CCU with AHF including patient demographics, prior medical history, precipitating 
factors for AHF, treatment and outcome. The main purpose was to assess the use of invasive 
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treatments (i.e. invasive revascularization and valve procedures) in relation to the etiology of 
AHF and compare its use with existing guideline recommendations. Patients presenting with 
cardiogenic shock secondary to acute coronary syndromes or valve pathology were 
individually assessed with regards to missed opportunities for revascularization or valve 
procedures.    
 
6.2 Paper II        
We observed a dismal short term prognosis for patients with the most severe forms of acute 
heart failure (i.e. cardiogenic shock and postcardiotomy heart failure) in our registry of 
patients with AHF presented in paper I. These very high early mortality rates have been 
reported in several publications and remain high despite extensive use of aggressive invasive 
treatments including revascularization and the use of intra-aortic balloon counterpulsation. An 
opportunity for improved outcome may lie in early institution of ventricular assist devices 
(VAD) in selected patients. The aim of this study was to identify the potential candidates for 
ventricular assist devices in the retrospective patient material presented in paper I and thus 
estimate the potential need for such therapy in the AHF population. Secondarily, we aimed to 
compare survivors vs. non-survivors with regards to patient demographics, prior medical 
history, precipitating factors for AHF and in-hospital treatment in order to identify potential 
predictors for in-hospital mortality. 
 
6.3 Paper III 
This was a pilot study conducted on patients undergoing open-heart surgery (CABG and valve 
replacement) at our institution. The aim was to study endothelial function (measured as flow 
mediated dilation) and circulating levels of ADMA and NO metabolites (NOx) during open 
heart surgery and look for possible relations between the two. Open-heart surgery served as a 
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controlled setting to observe these parameters from a preoperative baseline through the 
restitution after the cardiovascular and systemic trauma inflicted by such surgery with 
cardiopulmonary bypass.  
  Furthermore, this study served as a preparation for further studies on patients with the 
most severe acute heart failure presented in paper IV. A similar set of repeated endothelial 
function assessments and biochemical analyses were planned for both paper III and IV.  
Importantly, this pilot study could demonstrate if endothelial function measurements using 
brachial artery ultrasound were applicable in a clinical setting on critically ill patients.  
 
6.4 Paper IV 
The current understanding of the pathophysiology that render some patients with acute heart 
failure with an unfavourable course and lack of response to treatment is limited. This was 
evident in the recently published Triumph trial that addressed the possible adverse effects of a 
presumed overt production of nitric oxide secondary to inflammation in CS.127 Prior 
observational studies have suggested that systemic inflammation and neurohormonal 
activation plays an important role in cardiogenic shock.  
  In this observational study, patients with severe acute heart failure (i.e. cardiogenic 
shock and postcardiotomy HF) were followed up during the first part of their illness. The aim 
was to further characterize and try to establish the different factors modulating the circulation 
in these patients.  The main aim was to examine the changes and possible relation between the 
endogenous NO inhibitor asymmetrical dimethylarginine (ADMA), markers of inflammation 
and vasodilator function as a measure of vascular and endothelial function during the course 




6.5 Paper V  
Our interest and assessment of endothelial progenitor cells (EPC) were motivated by the 
original “Hill-observation” indicating that cardiovascular prognosis is related to the number of 
circulating EPCs.157 However, through our initial work with these colony-forming units 
grown in endothelial promoting media, it became apparent the true cellular lineage of these 
units was undefined and not necessarily related to endothelial progenitor or stem cells. Based 
on the work with these various cell lines, we made some observations clarifying important 
factors for EPC mediated angiogenesis. For instance, the utility of endothelial progenitor cells 
transplantation is potentially hampered by their low numbers in the circulation, impaired 
functional activity and importantly by inhibitory factors in the recipient causing poor cell 
survival and engraftment. These obstacles can possibly be circumvented by ex vivo priming 
of harvested cells or co-treatment with proangiogenic cytokines and peptides. In this study we 
examined the potential role of adrenomedullin to promote growth and angiogenic potential of 
cultured human late outgrowth EPCs.  
 
7. Materials and Methods 
The retrospective review and data collection of patients presented in paper I and II was 
approved by the Regional Ethics Committee (REK-Nord 51/2004) and the Norwegian Social 
Science Data Services (ref. 15293). The human observational studies presented in paper III, 
,IV and V were approved by the Regional Ethics Committee (REK-Nord 51/2004) and storing 
of human blood samples were approved by the Norwegian Directorate of Health (Biobank 
Registry no: 1045). Informed written consent was obtained from all study participants if 




7.1  Retrospective study of patients with acute heart failure (paper I and II)   
   
Data collection 
All patients admitted to the ICU or CCU through the years 2003-2004 with evidence of acute 
heart failure, whether present on admission or later in the hospital stay, were enrolled 
retrospectively. Eligible patients were screened based on discharge diagnosis of “heart 
failure”, “myocardial infarction” or “unstable angina”. Patients with AHF following major 
non-cardiac surgery (n = 22) were excluded, as for the majority of these patients cardiac 
dysfunction was secondary to serious underlying surgical conditions and multi organ failure. 
Data were collected by the investigators from medical records using a case report form that 
included patient demographics, prior medical history including cardiovascular disease, prior 
PCI/CABG, renal failure, diabetes and COPD. Precipitating factors and in-hospital invasive 
treatment were registered as reported. Results of laboratory tests, chest x-ray, 
echocardiography and clinical tests were all collected after the onset of AHF. Angiographic 
data referred were the most recent findings from the index hospitalisation. Data on in-hospital 
and two year mortality were obtained in 100% of the cases by matching all patients with the 
Norwegian Cause of Death Registry. 
 
Acute heart failure classification 
Patients were classified by the investigators into the following AHF conditions based on the 
current ESC guidelines6, 12 : Cardiogenic shock, Acute decompensated HF, Pulmonary 
oedema, Hypertensive AHF and Right HF. Less severe AHF was defined as all AHF 
conditions except CS and postcardiotomy HF. Description of clinical symptoms and signs 
(dyspnoea, rales, hypotension, hypoperfusion, peripheral oedema, increased jugular venous 
pressure and liver size), X-ray results and attending physician’s diagnosis were used for 
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verification of heart failure and classification into different clinical conditions on admission to 
the ICU/CCU. Patients with primarily infection, septic shock or other forms of high output 
failure were excluded. 
Postcardiotomy HF is not described in the ESC guidelines. We included patients with 
inadequate cardiac performance after surgery in need of inotropic and/or mechanical support 
lasting more than 2 hours.  
 
Evaluation of invasive treatment 
In order to clarify whether patients with acute heart failure received invasive treatment 
according to relevant guidelines, patients with AHF following ACS and/or severe valvular 
pathology were assessed for type of invasive treatment given. Patients with CS not receiving 
recommended invasive treatment where reviewed separately to assess eligibility for invasive 
treatment. Obvious contra indications included death occurring before intervention was 
possible, evidence of severe irreversible organ damage or the presence of concomitant severe 
life limiting disease. 
 
Identification of potential candidates for ventricular assist devices 
In order to assess the potential candidates for treatment with ventricular assist devices, non-
survivors with the most severe forms of acute heart failure, i.e. CS and postcardiotomy HF, 
were individually reviewed. Eligible patients were defined as all patients dying during 
hospitalisation despite maximal conventional treatment efforts. Secondarily, exclusion criteria 
were age above 75 years, pre-existing severe chronic heart failure, comorbidities with reduced 
life expectancy, severe peripheral vascular disease and evidence of permanent end organ 
damage or multi organ failure before institution of VAD treatment was considered feasible.  
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7.2 Endothelial function measurements 
There are several techniques for measurement of endothelial function.81 The “gold standard” 
is invasive measurement of change in coronary artery diameter, blood flow and vascular 
resistance secondary to intra coronary infusion of acetylcholine.212 As a substitute for direct 
measurements of coronary vascular reactivity there are several non invasive techniques 
measuring peripheral vascular reactivity to reflect systemic changes in endothelial function 
including the coronary arteries. The most widely used non invasive technique is ultrasound 
measurements of brachial artery dilation.213 This method measures the physiologic dilation of 
the brachial artery (conduit artery) induced by increased flow and shear stress acting on the 
endothelium. The magnitude of this vasodilatory response serves as an index of endothelial 
function and is referred to as flow mediated dilation (FMD). Another emerging method for 
measurement of peripheral vascular reactivity is the use of fingertip pulse amplitude 
tonometry using a finger plethysmograph.214 As opposed to FMD, a measure of conduit artery 
dilation, this method measures the microvascular vasodilator response in the fingertip. 
Although both techniques have been shown to correlate with several traditional cardiovascular 
risk factors and the two methods have some degree of agreement, some observations suggest 
that they do not interchangeably measure an equal vasculatory response.214-216  However, both 
methods have been shown to reflect NO-bioavailability.217, 218 Both techniques measure the 
distal vascular response to a transitory arterial occlusion resulting in local ischemia and 
subsequent reactive hyperemia when blood flow is re-established. The reactive hyperemia is a 
complex process involving metabolic vascular responses, myogenic responses, neuronal 
responses and endothelium dependent responses.219, 220 The principal mediators for the 
endothelium dependent dilation are NO, prostacyclin and endothelium-derived 
hyperpolarizing factor (EDHF). FMD measured in a strictly controlled setting is thought to be 
NO dependent and reflecting NO bioavailability. However, it is debated to what degree flow-
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mediated dilatation reflects NO mediated dilation.221-223 The relative importance of NO as 
opposed to other endothelial derived mediators seems to depend on methodology i.e level of 
occlusion, type of artery (vessel size), occlusion time and patient related factors (CAD- vs 
healthy). 
 
Brachial artery ultrasound measurements 
Bracial artery ultrasound imaging was used to measure flow mediated dilation in paper III. 
The diameter of the brachial artery was measured 5-10 cm proximal to the antecubital fossa 
using a Phillips iE33 ultrasound machine with a vascular probe (11 MHz), held in position by 
a stereotactic clamp after optimal visualization of the lumen-vessel wall interface. The vessels 
were scanned longitudinally using a 2D greyscale image and diameters were measured at end 
diastole. Reactive hyperemia was induced by occlusion with a blood pressure cuff on the 
proximal forearm and inflated to minimum 200 mmHg and at least 50 mmHg above systolic 
blood pressure for 5 minutes. Digital images were recorded at baseline and then continuously 
for 2.5 minutes during reactive hyperemia. Pulsed wave Doppler measurements were obtained 
within 15 seconds after deflation. A second resting baseline scan was performed 15 minutes 
after the first one. Images were analyzed using commercially available software with 
automatic edge detection of a selected segment of the artery (Brachial analyzer, Vascular 
research Tools 5.0.4, Medical Imaging Applications LCC, USA). FMD was expressed as the 
relative change (%) in vessel diameter after 60 seconds of hyperemia compared to baseline 
diameter. Flow was calculated from total averaging mean velocity (TAMV) measured at 
baseline and immediately after cuff release. Reactive hyperemia was calculated as hyperaemic 




Fig 1. Example of automatic edge detection and measurement of brachial artery diameter using the Brachial 
analyzer software on 2D grey scale ultrasound images. 
 
This technique has some limitations and requires skilled and experienced operators and is 
clearly user dependent. Being the most used and validated technique, FMD, was used to 
assess vascular function in paper III.  It was, however, apparent that it was difficult to adhere 
to the proposed recommendations for standardisation of FMD measurements in an intensive 
care setting and in the postoperative care with limited patient’s cooperation.213 For studying 
patients with acute heart failure the use of EndoPAT proved more feasible and had the 
advantage of being user independent. 
 
Peripheral arterial tonus measurements (EndoPAT)   
Endothelial function measurements presented in paper VI were assessed with non invasive 
digital pulse amplitude tonometry using the EndoPAT 2000 (Itamar Medical LTD, Caesarea, 
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Israel). This device provides measurements of the vasodilator function during reactive 
hyperemia with a fingertip plethysmograph measuring pulsatile volume changes in digital 
microvessels reflecting the peripheral arterial tone (fig 2.). 
 
 
Figure 2. Image shows baseline recordings of the pulsatile blood volume changes in the fingertip using the 
EndoPAT 2000. 
 
Measurements were performed bedside with patients in a supine position. Reactive hyperemia 
was induced by a 5 min. occlusion of the upper arm at approximately 60 mmHg above 
systolic blood pressure. Both sides were measured simultaneously to allow for adjustments of 
systemic changes in arterial tone by correcting for changes in the non occluded arm. Results 
were analysed using automated analysis software supplied by the producer (EndoPAT 2000 
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software version 3.1.2). This software calculates the ratio between baseline and hyperaemic 
pulsatile volume changes presented as a reactive hyperemia index (RH-index). 
 
 
Figure 3. Example of a normal hyperemic response recorded in a patient with acute heart failure using EndoPat 
2000. The blue segment marks the 5 min. occlusion period also seen by absence of signal in the occluded arm. 
The image shows a normal hyperemic response in a patient with acute heart failure.  
 
7.3 Endothelial progenitor cells and angiogenesis 
 
7.3.1 Cell isolation and culture 
Human endothelial progenitor cells were isolated from both patients undergoing open-heart 
surgery (from paper III) and healthy voluntaries (paper V). It was originally planned to use 
cells from patients for studies on late outgrowth EPCs and angiogenesis.  In patients 
undergoing surgery with manifest coronary heart disease we were, however, not able to 
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culture late outgrowth EPCs, probably due to the low number of cells in the circulation. We 
therefore used blood from healthy voluntaries for the experiments presented in paper V.    
 
Early outgrowth endothelial progenitor cells 
Blood samples from patients were isolated and cultured based on a previously described 
method.168 In short, mononuclear cells (MNC) were isolated by density gradient 
centrifugation, suspended in endothelial growth media (EGM-2, Bulletkit, Cambrex Bio 
Science) and cultured on 4-well culture slides coated with humane fibronectine. Non-adherent 
cells were removed on day 4 and cultures maintained until day 7 before staining. Cells were 
stained by incubation with Dil-labeled acetylated LDL and FITC conjugated lectin (Ulex 
Europaeus, UEA-1). Cells with endothelial phenotype positive for both lectin and Dil-ac-LDL 
were judged as early outgrowth EPCs and enumerated using an inverted fluorescence 
microscope (fig 4).   
 
Figure 4. Image of cultured early EPCs. a) 
Stained with Dil-labelled (red fluorescence) 
acetylated LDL. b) Stained with FITC-
labelled (green fluorescence) Ulex 








Late outgrowth endothelial progenitor cells 
Human mononuclear cells from freshly collected blood were isolated using density gradient 
centrifugation. The cells were suspended in endothelial growth media (EGM-2, Bulletkit, 
Cambrex Bio Science) and seeded at 5 x 106 cells/well onto six-well plates precoated with rat 
tail collagen type 1. Non-adherent cells were removed after 24 hours. Cultures were 
maintained until the appearance of typical late outgrowth EPC colonies with cobblestone 























Fig 5. Phenotypic characterization of late outgrowth endothelial progenitor cells (paper V). a) Confluent layer of 
EPCs in culture. b) and c): Immunofluorescence staining: Receptor activity modifying protein 2 (RAMP-2) (b) 
and calcitonin recepror-like receptor (CRLR) (c). d) and e): Confocal photomicrographs: platelet endothelial cell 
adhesion molecule (PECAM, CD31) (d) and VE-cadherin (CD144) (e).  Cell nuclei are counterstained with 
Draq5 (blue). f) Uptake of Dil-Ac-LDL. g)  Real-time PCR results of the relative mRNA expression of relevant 
genes to characterize EPCs compared with human umbilical vein endothelial cells (HUVEC) and mononuclear 
cells (MNC). * No expression. # p = 0.001 compared with EPC. VEGFR-2, vascular endothelial growth factor 
receptor 2. 
 
7.3.2 In vitro proliferation and angiogenesis assay 
EPC proliferation was assessed using CELLTiter 96 Aqueous One Solution Cell Proliferation 
Assay (Promega), a colorimetric determination of viable cells based on the bioreduction of a 
tetrazolinum compound (MTS) in metabolically active cells.  
 To assess the angiogenic properties of EPCs we used a previously described coculture 
assay.187, 224 Human fibroblasts (MRC5) were seeded onto a 24-well culture plate and allowed 
to grow to confluence. EPCs (1 X 104) were added and cocultures were grown for 14 days in 
EGM-2 (without VEGF) with the addition of either adrenomedullin (AM) or vascular 
endothelial growth factor (VEGF). Finally, cocultures were fixated and stained with CD31. 
Tubular networks were photographed with an inverted fluorescence microscope. In addition, 
we used a short-lasting (18 h) angiogenesis assay with 24-well culture plates coated with 
Growth Factor Reduced Matrigel Matrix (BD Biosciences). Culture plates were photographed 
using an inverted light microscope. The extent of tubular networks in both assays were 





8. Summary of results and discussion 
 
8.1 Summary of results Paper I   
A total of 324 patients diagnosed with acute heart failure were treated at the CCU and/or ICU 
during the two year observation period. The timing and location of AHF onset is shown in 
figure 6. The majority of patients (62 %) presented with signs of acute heart failure on 
admission to the hospital, while 25 % occurred after intervention. The distribution of the 
different clinical AHF conditions is shown in figure 7.  
 

















Figure 6. Timing of acute heart failure (AHF) onset. a) Includes also patients without postcardiotomy HF 






Figure 7. Distribution of the different 
acute heart failure conditions admitted 
to the intensive care unit/coronary care 
unit at the University Hospital of 




Less severe forms of AHF (i.e acute decompensated heart failure, pulmonary edema, 
hypertensive acute heart failure and right heart failure) accounted for 62 % of the patients. 
The most severe forms of AHF, CS and postcardiotomy heart failure were seen in 23 and 15 
% of the patients, respectively. CS patients were on average younger (69 years) compared 
with less severe forms of AHF (75 years). Cardiovascular comorbitities were abundant in the 
overall population with half of the patients presenting with a history of coronary heart disease 
and 40 % had prior myocardial infarctions. Prior invasive revascularization, PCI (12 %) and 
CABG (14%), had been done in one-fourth of the patients. Acute coronary syndromes were 
by far the most common precipitating factors for acute heart failure (57 %). The vast majority 
of these patients had evidence of acute myocardial infarction. A large proportion, 30 %, 
presented with arrhythmias usually concomitant to other precipitating factors. Severe valvular 
dysfunction was observed after acute heart failure onset and considered as a precipitating 
factor in 12 % of the overall population and in 20 % of CS patients. 
 Angiography was performed during the index hospitalisation in 42 % of all patients 
and most frequently in CS patients (70 %). Three-vessel disease was present in 40 % of the 
angiograms. The majority of patients had a normal or moderately reduced left ventricular 
ejection fraction regardless of clinical class. Creatinine levels increased on average for all 
groups during hospitalization. Hyponatremia was present in 9 % on AHF onset, while 
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abnormal serum potassium was present in 37 %. Biochemical markers of cardiac injury were 
significantly higher in CS patients compared to less severe forms of AHF, but not compared 
to postcardiotomy HF and right HF. 
 
Mortality 
The overall in-hospital mortality was 24 %. There was no major difference in mortality 
between AHF secondary to acute coronary syndromes versus the overall mortality for AHF. 
CS had the worst in-hospital morality (46 %) and the majority of fatalities occurred within 
two days after admission. In comparison, less severe forms of AHF had a far better short-term 
prognosis with an in-hospital mortality rate of 13 %. Two-year survival was worse for CS 
compared to postcariotomy HF (Log-Rank p = 0.004) and other less severe AHF conditions 
(Log-Rank p < 0.001), while no difference was observed between postcardiotomy HF and less 
severe AHF (Log-Rank p = 0.064). Two-year mortality rates for hospital survivors were 
similar when comparing CS and less severe AHF conditions (p = 0.709), while a significantly 
better two-year survival was observed for the discharged postcardiotomy HF patients (p = 
0.009). Mortality rates by the major AHF conditions are shown in figure 8a. Two-year 
Kaplan-Meier survival curves are shown in figure 8b. 
 Invasively treated patients (revascularization, valvular surgery and other acute cardiac 
surgery) in the overall population with less severe AHF had lower in-hospital mortality 
compared to patients treated conservatively (6 % vs. 17 %, p = 0.042). This was similar in the 
subset of patients with acute coronary syndromes (6 % vs. 20 %, p = 0.028). Furthermore, CS 
patients treated invasively had improved outcome both in the overall population (35 % vs 70 
%, p = 0.006) and when CS was secondary to ACS (34 % vs. 80 %, p = 0.009). There was no 
statistically significant difference in mortality between CS patients treated with CABG versus 






























Figure 7. a. All-cause mortality rates by clinical class. b. Kaplan-Meier plot of two-year survival. 
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Invasive treatment of acute heart failure following acute coronary syndromes 
Angiographic examination was performed during hospitalisation in 68 % of all patients with 
ACS, while 65 % received invasive revascularization. PCI was the treatment of choice in 
most patients (48 %) and CAGB was performed in 17 %. One patient with CS received both. 
Revascularization was more frequent among CS patients compared to other less severe AHF 
conditions (78 % vs. 58 %, p = 0.012). Mechanical circulatory support was used in 22 % of all 
patients with ACS. CS and postcardiotomy HF patients were treated with IABP in 
respectively 45 % and 70 % of the cases. CS patients also received mechanical ventilation 
(intubation) in a majority of the cases (59 %). Cardiac surgery for mechanical complications 
following ACS, such as rupture of the ventricular septum or free wall, acute mitral 
regurgitation, cardiac tamponade or concomitant chronic valvular pathology, was performed 
in 8 %. Most of these procedures were done in combination with surgical revascularization. 
 PCI and/or CABG were not performed in 11 (22 %) of CS patients with ACS during 
this first part of their illness. An individual review revealed that only four of these patients (8 
%) were untreated potential candidates for coronary angiography and invasive treatment. 
None of these patients received thrombolytic therapy. All were octogenarians with a history 
of MI or prior invasive revacularization and none survived the index hospitalisation. In 
addition, two patients were discharged alive after successful medical reperfusion confirmed 
by angiography. The presence of severe comorbidities was the reason for not performing 
angiography in those patients where this was technically feasible. 
 
Valvular pathology 
Mitral valve dysfunction was the most abundant valvular pathology and moderate or severe 
mitral regurgitation (MR) was present in almost one-third of all the patients. Severe MR was 
observed in 13 % (n = 8) of CS patients and seven of these patients had acute myocardial 
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infarction. Only one patient received urgent surgery due to a ruptured papillary muscle while 
the remaining patients were revacularized or treated conservatively. Three patients presented 
with severe aortic stenosis (AS). In two patients CS was primarily due to worsening AS and 
they received acute aortic valve replacement. One patient had concomitant AMI and was 
revascularized.  Three patients presented with severe aortic regurgitation. Valvular 
dysfunction was the main precipitating factor for CS in two patients and one received valve 
replacement while the other was treated conservatively due to high age and severe 
comorbidities. One patient presented with concomitant AMI and was revascularized without 
any valvular surgery.  
 In the less severe AHF conditions, severe MR was observed in 6 % (n = 10) while 
severe aortic valve dysfunction was observed in 8 % (n = 13) of the examined patients. 
Valvular surgery was performed during index hospitalisation in only three patients with 
severe MR due to rupture of the papillary muscle and endocarditis. 
 
8.2 Summary of results Paper II  
Severe acute heart failure was present in 42 % of the over all population with acute heart 
failure (cardiogenic shock 23 %, postcardiotomy HF 19 %). 18 % of patients with 
postcardiotomy HF had some form of less severe heart failure before surgical treatment.  
 Survivors in the cardiogenic shock group were younger (64 vs. 75 years) and were less 
likely to have a history of coronary heart disease (24 % vs. 47 %), hypertension (19 % vs. 50 
%) and peripheral vascular disease (0 % vs. 16 %). There were no major differences between 
survivors and non-survivors in the postcardiotomy HF group with regards to prior medical 
history and patients demographics. There was, however, a significantly higher proportion of 
patients with AHF secondary to valve replacement surgery among non-survivors. Cardiogenic 
shock survivors were treated more invasively with CABG (32 % vs. 6 %), mechanical 
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ventilation (70 % vs. 34 %) and IABP (57 % vs. 28 %) compared to non-survivors. Treatment 
with PCI (41 % vs. 46 %) was equal in the two groups.  
 In a multivariate analysis, valvular surgery, female gender and high creatinine levels 
were independently associated with adverse outcome for patients with postcardiotomy HF. 
For cardiogenic shock patients a history of hypertension and advanced age was associated 
with increased risk, while undergoing CABG during hospitalisation was associated with 
increased survival. 
 Among non-survivors, 27 patients were younger than 75 years. Serious comorbidities 
and/or evidence of end-organ damage were present in 12 patients, making them unsuitable for 
treatment with ventricular assist devices. The remaining 15 patients were deemed eligible for 
VAD treatment and they accounted for 14 and 9 % of patients with CS and postcardiotomy 
HF, respectively. Nine of these patients presented with CS secondary to AMI complicated 
with refractory cardiogenic shock after treatment with an early revascularization strategy.    
 These figures indicate that mortality of potential VAD candidates on the indication 
acute heart failure is 15/million inhabitants/year.  
 
8.3 Discussion paper I and II 
 
Invasive treatment and mortality in cardiogenic shock 
In our cohort of patients, there was an extensive use of invasive revascularization for patients 
with cardiogenic shock following ACS. Appropriate selection of CS patients for invasive 
revascularization was confirmed by an individual review of cases receiving conservative 
treatment.  These patients were octogenarians with partly severe comobidities or previous 
revascularization attempts, and three out of four had non-STEMI.  These aspects are likely to 
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have affected the decision towards conservative treatment and thus indicate an appropriate 
clinical selection of patients for invasive treatment.  
A revascularization frequency of 78 % for CS patients in our survey was substantially 
higher than reported from EHFS-II and the GRACE registry.12, 56 We did not, however, 
observe a more satisfactory in-hospital outcome compared to the EHFS-II. One possible 
explanation could be that aggressive revascularization is associated with increased early 
mortality compared to conservative treatment and that the beneficial effects are seen later on, 
as was the case in the SHOCK trial. In this trial, patients receiving early revascularization had 
a high early mortality rate of 47 %.225 Mortality rates for CS of any cause in our material were 
comparable with the early and long term mortality rates found in the French EFICA study and 
another published study from Rudiger et al. probably reflecting a similar patient selection.7, 11 
Importantly, survivors of the initial event among CS patients had a relatively good long-term 
prognosis comparable to other less severe forms of AHF.11, 226-228 
 Compared to other patient materials, the use of surgery (24 %) was high in CS 
secondary to ACS.12, 16, 56 In our survey, patients who were revascularized by means of 
CABG had an 85 % in-hospital survival compared to 57 % in patients treated with PCI, but 
this was not statistically significant in our relatively small patient cohort. Also, different 
patient selection and timing of the two interventions could affect these figures. 
 Valvular pathology was quite common in CS and the rate of severe mitral 
regurgitation (13 %) was comparable with the findings in EHFS-II, but higher than reported 
from the SHOCK trial registry (7 %).41 In the majority, MR was secondary to left ventricular 
dysfunction and treated with revacularization or conservative treatment only. In contrast, 
close to half of the patients with severe MR in the SHOCK trial registry received valvular 
surgery.68 A different incidence of the two conditions could potentially explain both the 
occurrence and management of these patients. In addition, there is no definite evidence 
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guiding the choice between revascularization and stabilisation versus prompt valve repair or 
replacement when MR follows left ventricular dilatation in acute heart failure. Patients with 
aortic valve dysfunction received valve replacement when this was technically feasible and 
there were no major contraindications.  
 The use of intra-aortic balloon counterpulsation (45 %) was surprisingly low despite 
being a recommended therapy for CS in particular. Although our figures were better than 
reported from the NRMI registry (39 %) and EHFS-II (31 %), IABP was used more 
frequently in the SHOCK trial registry (53 %).12, 16, 41  This revealed a potential under-
utilization of mechanical assistance and since this survey, we have instituted IABP as a 
routine modality in CS. 
 
Invasive treatment and mortality in less severe acute heart failure 
A substantially higher frequency of invasive revascularization was observed in our material 
(58 %) compared to the NRMI and GRACE registries.66, 67 Despite similar in-hospital 
mortality rates on 14 %, the reported long term survival in the GRACE registry was better. 
This reflects the strikingly high intermediate-term mortality for hospital survivors observed in 
our patients. A selection of CCU/ICU patients and not the general AHF population, could 
explain this difference. Mortality rates for less severe forms of AHF of any cause were also a 
lot higher than reported in EHFS-II and other studies 7, 10, 12, but comparable to the findings in 
the EFICA study on ICU/CCU patients 11. 
 Severe valvular dysfunction was less frequent in less severe AHF compared to CS, 
mostly due to a difference in the presence of severe mitral regurgitation. There was however, 
no major difference in the frequency of valvular surgery in this group compared to 
cardiogenic shock, and surgical treatment of acute mitral regurgitation was only performed in 
the setting of acute papillary muscle dysfunction or rupture and endocarditis.  
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 The dismal long term prognosis for patients with less severe forms of AHF underlines 
the need for close surveillance after discharge in this CCU/ICU treated population. 
 
Postcardiotomy HF 
Postcardiotomy HF constituted a significant part of the total AHF population treated in the 
CCU/ICU. Short term prognosis was dismal compared to less severe forms of AHF, but better 
than for CS. Two-year mortality for hospital survivors was, however, substantially better 
compared to any of the other AHF conditions. These patients are all treated with complete 
surgical correction, and for logistical reasons, always receive a high level of medical attention 
and surveillance, making early application of appropriate therapy possible. The extent of 
myocardial damage was comparable to CS as judged by peak CK-mb.  
 
Candidates for ventricular assist devices 
The utilization of ventricular assist devices in the setting of acute CS is not well established. 
In the SHOCK Trial Registry only 0.8 % of the patients received this treatment. 41 A 
substantially higher use of VAD therapy (12 %) was, however, reported in the more recent 
TRIUMPH Trial on patients with CS persisting after revascularization.127 Tayara et al. 
reported similar figures on VAD use (13 %) on a series of consecutive patients with CS after 
AMI.75 Our estimate of potential candidates for VAD therapy on 14 % in CS is in agreement 
with these publications.  
 The use of VADs in the setting of postcardiotomy HF is a more widespread and 
accepted therapeutic intervention. In the US “Society of Thoracic Surgeons’ National Cardiac 
Database” this intervention was used in 0.3 % of all open heart operations with a reported 
operative short term mortality on 40 %.30 Others have reported similar figures on the 
incidence of severe postcardiotomy HF requiring VAD therapy ranging from 0.2-1.2 %.27-29, 
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31-33 The estimated need for VAD therapy on 0.4 % of all open-heart operations in our survey 
is well within the range of these reports.  
 As expected, older patients were overrepresented among non-survivors with 
cardiogenic shock and advanced age was independently associated with increased mortality. 
This was not evident in postcardiotomy HF and this could possibly be due to a selection of 
patient scheduled for open heart surgery based on a total risk assessment with the result that 
they are otherwise healthier compared to their younger counterparts. A prominent feature in 
postcardiotomy HF was a substantially increased risk for females and patients undergoing 
valvular procedures. Female gender is a well established risk factor in open-heart surgery. All 
the potential VAD candidates in our material with postcardiotomy HF underwent aortic valve 
replacement surgery with or without concomitant coronary revascularization. This reflects the 
overall increased risk of perioperative complications following valve procedures compared to 
isolated coronary revascularization. However, in the largest registry to this date VAD therapy 
was by far most frequently applied after isolated coronary revascularization.30 
 
Concluding remarks 
The most severe forms of acute heart failure, i.e. cardiogenic shock and postcardiotomy HF, 
include a spectrum of patients with different prognosis and degrees of hemodynamic 
compromise. This heterogeneity and the extremely high mortality in subgroups of these 
patients mandates an effort to develop more precise diagnostic algorithms to grade the most 
severe forms of heart failure to ensure a timely and proper selection of patients that can 





8.4 Summary of results Paper III 
In this study we included a total of 27 patients scheduled for standard coronary bypass surgery 
(CABG, n = 22) or isolated valve procedures (n = 5).  This study also served as a pilot study 
for the planned study on patients with severe acute heart failure using a similar design. All 
patients were assessed preoperatively (baseline) and the following three postoperative days 
with repeated measurements of endothelial function (flow mediated dilatation, FMD) and 
determination of circulating levels of NOx and asymmetric dimethylarginine (ADMA). 
  Open heart surgery significantly affected the endothelial function with a marked 
attenuation in FMD on the first postoperative day compared to baseline (4.1 % vs. 1.4 %, p < 
0.001). This effect was only transient as FMD returned to baseline levels on the second and 
third postoperative day. This is shown in figure 9. 
 
Figure 9. Flow mediated dilation during 
open-heart surgery (n = 25). Lines denote 






Patients undergoing isolated valve surgery did not have any evidence of coronary heart 
disease on coronary angiography. As expected their baseline FMD was higher than for CABG 
patients (8.1 % vs. 3.1 %, p = 0.005). A similar attenuation of FMD was, however, evident in 
both groups when analysed seperatively (valve surgery: 8.1 % vs. 3.7 %, p = 0.026, CABG: 
3.1 % vs. 0.9 %, p < 0.002). 
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Open heart surgery affected circulating ADMA levels uniformly with significantly lower 
levels postoperatively compared to baseline (Friedmans ANOVA χ2 = 29.3, p < 0.001). 
Postoperative ADMA levels remained significantly suppressed compared to preoperative 
levels at all the measured time points after correction for multiple comparisons (p ≤ 0.002, 
Figure 10a). Surgery also suppressed plasma NOx levels (n = 27, Friedmans ANOVA χ2 = 
24.1, p < 0.001). Reduced postoperative NOx were found at all measured time points after 
correction for multiple comparisons (p ≤ 0.05, Figure 10b). 
 
Figure 10. ADMA (asymmetric 
dimethylarginine) and NOx (nitric oxide 
metabolites) during open-heart surgery 
(n = 27). Lines denote median values. 














FMD measurements did not correlate with ADMA/NOx levels at any of the measured time 
points. Baseline levels of ADMA and NOx did not correlate, but there was a significant 
positive correlation between NOx on the first postoperative day and ADMA levels on baseline 
and the first postoperative day (r = 0.46, p = 0.016, r = 0.45, p = 0.020). Repeating the 
analysis with NOx indexed to creatinine did not change this relation. 
  
8.5 Summary of results Paper IV  
The study population consisted of 24 prospectively included patients admitted with either 
cardiogenic shock or postcardiotomy HF at the University Hospital of North Norway between 
2007 and 2009. After inclusion, patients were followed with repeated assessment of 
peripheral vasodilator function, markers of inflammation and endothelial activation, and the 
endogenous NO inhibitor ADMA. 
In-hospital mortality rates were 42 % and 17 % for respectively CS and 
postcardiotomy HF patients. A marked elevation in the inflammatory markers IL-6 and 8 in 
the first 1-2 days was a prominent feature in both groups.   
The serial assessment of peripheral vasodilator function is shown in figure 11. RH-
index was impaired at baseline in both groups (CS: 1.35, P = 0.001, Postcardiotomy HF: 1.45, 
P = 0.001) compared to control (2.28). This was not uniform as several individuals presented 
with preserved RH-index indicating a preserved vascular and endothelial function. No 
significant changes were seen in RH-index through days 1-4 for CS patients. However, for 
postcardiotomy HF patients the RH-index increased through the observation period (p = 
0.019) and was significantly higher at days 3 and 4 compared with baseline (p = 0.011). The 
longitudinal changes in RH-index were not associated with the concomitant changes in 
ADMA levels. We observed, however, a negative correlation between ADMA and RH-index 
(r = -.633, p = 0.036) at baseline for CS patients. 
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Figure 11. Reactive hyperemia index (RH-index) measured at days 1-4. a) Mean RH-index with SEM. 
Induvidual values of the repeated RH-index measurements for CS patients b) and postcardiotomy HF patients c). 
* p < 0.05 compared with day 1. # p < 0.05 compared with CS and postcardiotomy HF at day 1. 
 
Interestingly, the resolving inflammatory response with falling levels of IL-6 and IL-8 
observed in postcardiotomy HF patients was associated with the improving RH-index in these 
patients. 
The measured ADMA levels are shown in figure 12. While baseline ADMA levels in 
CS and healthy controls were grossly similar (0.74 vs 0.79 µmol/L), they were on average 
significantly lower in postcardiotomy HF (0.55 µmol/L, p = 0.04). ADMA levels increased 
during the observation period for postcardiotomy HF patients, but remained unchanged in CS. 
There were no associations between day-to-day changes in ADMA and markers of 
inflammation and endothelial activation. However, patients who underwent cardiopulmonary 
resuscitation prior to CS onset had significantly higher baseline ADMA levels (1.05 vs 0.58 
µmol/L, p = 0.003). Also, ADMA levels correlated with lactate levels measured at baseline (r 




Figure 12.  The course of plasma ADMA levels measured at days 1-4. a) Mean plasma ADMA with SEM. 
Individual changes in plasma ADMA levels for CS b) and postcardiotomy HF c). * p < 0.05 compared with day 
1. # p < 0.05 compared with postcardiotomy HF at day 1. 
 
In order to look for relations between organ dysfunction and the measured variables 
we used the Sequential Organ Failure Assessment (SOFA) score229 to assess the extent of 
organ dysfunction. CS patients with failure of an organ (excluding the central nervous system 
or cardiovascular system) had lower baseline RH –index (median 1.22 vs 1.51, p = 0.01) and 
elevated ADMA levels (median 0.58 vs. 1.05 µmol/L, p = 0.005). Moreover, SOFA score was 
correlated to baseline RH-index (r = -.69, p = 0.014), baseline ADMA levels (r = .63, p = 










8.6 Discussion paper III and IV 
 
Acute changes in endothelial function 
The endothelial function following open heart surgery and at the onset of acute heart failure 
was impaired. In patients undergoing surgery, both elective patients and patients with 
subsequent postcardiotomy heart failure, this impairment was transient. A postoperative 
reduction in FMD has been described previously.230, 231 This indicates that an acute systemic 
vascular dysfunction likely to influence on the vessels’ ability to regulate vascular tone and 
blood flow takes place following open-heart surgery. Patients with cardiogenic shock showed 
a similar impairment in endothelial function compared with healthy controls. Prior studies 
have demonstrated attenuated increase in forearm blood flow during reactive hyperemia in 
patients with cardiogenic and septic shock.86 A similar impairment has also been described in 
patients with severe sepsis and septic shock using peripheral arterial tonometry (similar to 
paper IV).87, 88 The underlying mechanisms for this attenuation in endothelial functions are 
likely to be multifactorial, and probably involve a composite of prior vascular /endothelial 
function and a multitude of superimposed acute factors including vasoactive treatment. The 
peripheral vasculature in patients with severe hear failure, and in the course of acute heart 
failure, is subject to immense and changing stimuli from circulating hormones, the 
sympathetic nervous system and local metabolic factors capable of modulating both 
endothelial and vascular function.232-234  The bioavailability of NO is considered the main 
determinant for endothelial function measured with both brachial ultrasound and PAT81, 213, 
217, 218 and thus these findings could indicate reduced NO bioavailability in these patients. We 
observed a negative correlation between the endogenous NO- inhibitor ADMA and 
endothelial function at baseline for CS patients that could suggest an inhibitory effect of 
ADMA on vascular function. There was, however, no apparent assosciation at baseline or 
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longitudinally during follow up between circulating levels of NO metabolites (open heart 
surgery patients) or ADMA (all patients).  It is possible that attenuation of other important 
contributors to endothelium dependent dilation, such as prostacyclin or endothelium derived 
hyperpolarizing factor, play a bigger role in these patients. Also, fewer functional capillaries 
secondary to intravascular obstruction or oedema could blunt the reactive hyperemic response 
in critical disease.235 Importantly, for patients undergoing surgery with CPB changes in blood 
viscosity due to perioperative blood loss and hemodilution could affect shear stress acting on 
the endothelium in the early postoperative period and the hemodilution will also affect the 
levels of circulating proteins and metabolites.236       
 
Inflammation 
In our study, patients with CS and postcardiotomy HF were subject to a profound 
inflammatory insult evident by excessive levels of the circulating inflammatory cytokines IL-
6 and IL-8 that resolved during follow-up. This was markedly higher than reported in less 
severe heart failure and acute myocardial infarction121, 122, 237 and comparable to the levels 
measured in sepsis87, 120, 238. High levels of IL-6 in CS patients were related to both low MAP 
and vasopressor requirements. The association between IL-6 levels and vasopressor support 
has been described earlier.50 However, we observed no correlation at baseline or longitudinal 
association between the degree of inflammation and endothelial function to support that the 
observed vascular dysfunction was due to inflammation. Interestingly, the observed 
improvement in vasodilator function in postcardiotomy HF patients was associated with the 
resolving inflammatory response. Although the systemic inflammatory insult and endothelial 
activation inflicted by open-heart surgery and use of extra corporeal bypass is well 




In line with previous observations, we observed suppressed postoperative levels of circulating 
ADMA after open-heart surgery.241, 242 Initially low ADMA levels that increased during 
follow up were also observed at the onset of postcardiotomy HF. This could possibly be 
caused by a hemodiluting effect of extra corporeal circulation.243, 244 In contrast to previous 
reports on acute decompensated heart failure and CS, ADMA levels in patients with CS were 
not different from healthy controls in our study.146, 149  
 ADMA levels did correlate with endothelial function at baseline for CS patients. This 
was not the case in postcardiotomy HF, and furthermore there were no associations between 
the longitudinal changes in ADMA and endothelial function in either group. Similarly, 
ADMA did not correlate with FMD measurements in patients undergoing open-heart surgery. 
Furthermore, ADMA did not relate to blood pressure or hemodynamic measurements. All 
together these studies gave no indication that the ADMA-DDAH pathway was responsible for 
the reduced endothelial function. The circulating plasma levels of ADMA do, however, not 
necessarily reflect intracellular ADMA levels or tissue levels in specific organs. Thus, a 
biological relevant NO-inhibitory effect can take place without a change in circulating levels. 
 In line with observations on patients with severe sepsis and critically ill patients, 
elevated ADMA levels were associated with the degree of organ dysfunction and elevated 
systemic lactate151-153. The observation that ADMA levels were highest in the patients that 
underwent CPR and had elevated lactate could indicate that ADMA reflects the degree of 
hypoperfusion during shock. Interestingly, patients with evidence of organ failure did not 





8.7 Summary of results Paper V  
The cultured late outgrowth endothelial progenitor cells expressed an endothelial phenotype 
as presented in fig 5. Moreover, EPCs stained positive for the CRLR and RAMP-2 and this 
was also found at the mRNA level using Real-time PCR (fig 5g). The addition of 
adrenomedullin (AM) increased proliferation in a dose-dependent manner. This was 
suppressed by the addition of the AM antagonist AM 22-52. Inhibition with the 
phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin, abolished the AM-induced 
proliferation while no such effect was seen using a MEK ½ inhibitor. Also, the addition of 
AM produced a 36 % relative increase in tubular network formation in the EPC/fibroblast 
coculture assay, compared with controls (fig 12).  A similar proangiogenic effect of AM 
stimulation was seen in the matrigel assay were we observed an 80 % increase in tubular 
network formation (fig 13). The proangiogenic and growth promoting effects of 
adrenomedullin was similar to that of VEGF. Addition of the AM antagonist AM 22-52 and 
PI3K inhibitor wortmannin blunted the increased tubule formation seen on the matrigel assay. 
Non-stimulated EPCs secreted IL-6 and IL-8. There was an early augmentation in the 
secretion of these cytokines following AM stimulation (2 hrs) that was accompanied by a 
two-fold increase in the expression of IL-6 and IL-8 mRNA. There was, however, no change 
compared to non-stimulated cells at 20 hrs. Furthermore, AM did not seem to affect EPC 






Figure 12. Tubule formation in EPC/fibroblast coculture. a-c) Representative images of CD31 stained tubules. a) 
Control. b) Addition of adrenomedullin (10-7 M). c) Addition of vascular endothelial growth factor (50 ng/ml). d) 
Confocal image of CD31 positive tubules. Cell nuclei counterstained with Draq5 (blue). e) Measured tubule 
length presented as percentage of control (±SD). * p < 0.05 compared with control. AMBP-1, adrenomedullin-
binding protein 1.   
 
 
Figure 13. Tubule formation on matrigel matrix. a) Control. b) Addition of adrenomedullin (10-7 M). c) Addition 
of vascular endothelial growth factor (50 ng/ml). d) Addition of AM plus VEGF. e) Measured tubule length 
presented as percentage of control (±SD). * p < 0.05 compared with control.  
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8.8 Discussion paper V  
This is the first study to demonstrate that human late outgrowth EPCs express the AM-1 
(CRLR/RAMP-2) receptor complex, and importantly AM both enhances cell growth and the 
proangiogenic properties of these cells. Similar observations have previously been made for 
early outgrowth EPCs were AM suppress apoptosis and increase cell numbers.207 Importantly, 
coadministration of AM augments the angiogenic effects of unspecified bone marrow-derived 
mononuclear cell transplantation in models of ischemia.206, 209 These studies suggest a potent 
stimulatory role of AM in both EPCs and other cells with stem cell potential and thus its 
potential usefulness in therapeutic angiogenesis and vascular repair. 
 The AM-induced EPC proliferation and increased tubular network formation seem to 
be mediated through the PI3K/akt signalling pathway, demonstrated by the inhibitory effects 
of wortmannin. This pathway regulates several important steps in angiogenesis including 
endothelial cell proliferation, migration and capillary formation. This pathway also seems to 
mediate the antiapoptotic actions of AM on early EPCs.207 While prior studies have shown 
that AM also induces proliferation of mature endothelial cells and angiogenesis through the 
activation of MAPK, this was not evident in the EPCs in our study using the MEK ½ inhibitor 
UO126.204  
 We found no evidence that AM acted through increased release of VEGF or 
expression of VEGF mRNA. Nor did AM affect the expression of the VEGFR -2.  Prior 
reports on different populations of cultured endothelial cells have, however, shown conflicting 
results.206, 210, 245-247 It has also been suggested that AM can act through transactivation of 
VEGFR-2 and thereby induce a proangiogenic signalling cascade.246 
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 In line with earlier studies on late outgrowth EPCs, we found a secretion of IL-8 under 
basal culture conditions.248, 249 They also secreted IL-6, as previously observed in mature 
endothelial cells.250 Both IL-8 and IL-6 are shown to stimulate endothelial cell proliferation 
and act proangiogenic.251-254 In EPCs, IL-8 seems to contribute substantially to the cells’ 
paracrine mitogenic effects while IL-6 has been shown to increase cell proliferation and act 
proangiogenic.248, 255 Our observations suggest that AM induces an early release of these 
cytokines. However, this stimulated release was small and transitory and a substantial 
proinflammatory effect was not observed. An indirect proangiogenic effect of AM through 
increased release of these cytokines cannot, however, not be ruled out. 
 
9. Main conclusions 
Paper I 
- There was an extensive use of invasive revascularization in patients with cardiogenic 
shock following an acute coronary syndrome. Eligible patients who were not treated 
with early revascularization where in their eighties and presented with complicated 
comorbidities. The role of aggressive invasive therapy in this patient group is more 
illusive. 
- Early mortality in CS was very high despite the extensive use of invasive 
revascularization and the majority of in-hospital deaths occurred within two days. 
More than one third of invasively treated patients died while in hospital adding further 
evidence to the limitations of invasive treatment in CS. There should be an effort to 
develop precise diagnostic algorithms to grade CS and its prognosis, to improve the 
initial medical therapy and probably to establish an early institution of temporary 
assist systems in selected patients. 
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- Despite extensive use of invasive revascularization in patients with less severe AHF 
compared to other reports, a significant number of patients did not receive this 
treatment. This could indicate a potential for increased use of early invasive treatment 
in this high risk population. The strikingly high intermediate-term mortality even 
compared to more severe forms of AHF, further underlines this. 
- Mitral regurgitation was a contributing factor for the development of AHF in a 
significant number of patients. Mitral valve surgery was in our population only 
performed in the setting of acute papillary muscle rupture or endocarditis while mitral 
regurgitation secondary to left ventricular dysfunction was treated with 
revascularization and medical stabilization. To what extent mitral valve procedures 
should be done in the setting of AHF and cardiogenic shock, is for now unknown. 
- Postcardiotomy patients constitute a significant proportion of the AHF population and 
should ideally be included in AHF registries. The sickest patients are often treated 
surgically, at times also with supportive invasive therapy for refractory circulatory 
shock.  Also, postcardiotomy heart failure has many pathophysiological aspects in 
common with the other groups of AHF patients, and they need to be included in the 
development of new treatment algorithms. 
 
Paper II 
- Application of mechanical circulatory support by means of ventricular assist devices 
represents an important alternative for improving prognosis in severe acute heart 
failure (i.e. cardiogenic shock and postcardiotomy HF). 
- In this retrospective study we found 12 % of these patients to be potential candidates 
for treatment with ventricular assist devices. The observed incidence in our material 
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indicates a mortality of potential VAD candidates with acute heart failure on 
15/million inhabitants/year.  
- Female patients with inadequate cardiac pump function after valve replacement were 
at the highest risk of dying despite maximal conventional treatment efforts. 
 
Paper III 
- Open heart surgery with the use of cardiopulmonary bypass induces a temporary 
attenuation in flow mediated dilation in both patients with healthy endothelium and 
manifest atherosclerotic disease. 
- There were no association between circulating levels of NOx (nitrite + nitrate), 
ADMA (asymmetric dimethylarginine) and the attenuated endothelial response. 
 
Paper IV 
- Cardiogenic shock and postcardiotomy HF were characterized by initially elevated 
levels of inflammatory cytokines suggestive of a profound inflammatory insult.  
- This acute inflammatory response was accompanied by an attenuated vasodilator 
function in both groups. Vasodilator function improved during the observation period 
for patients with postcardiotomy HF and this improvement was associated with a 
resolving inflammatory response. This relation was, however, not evident in CS 
patients. The repeated assessment of vasodilator function revealed a substantial 
individual day to day variation suggesting that vascular function in acute disease is not 
static. 
-  The circulating levels of the endogenous NO-inhibitor ADMA did not relate to the 
degree of inflammation or the day-to-day changes in vasodilator function. 
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- In CS, ADMA, vasodilator function and levels of inflammatory cytokines correlated to 
the overall degree of organ dysfunction and to hepatic dysfunction in particular. 
- The increased ADMA levels observed in patients who underwent CPR and/or had 
elevated arterial lactate levels suggest a relation between ADMA and the degree of 
hypoperfusion in CS. 
-  This study demonstrated that EndoPAT was a feasible technique for repeated 
measures of peripheral vasodilator function in the intensive care setting.  
 
Paper V 
- Late outgrowth endothelial progenitor cells possess an endothelial phenotype and 
express the adrenomedullin 1 receptor complex (CRLR/RAMP-2). 
- Adrenomedullin stimulation induced proliferation of EPCs and a marked increase in 
formation of tubular networks in vitro in a similar fashion to that of VEGF. 
- The proliferative and proangiogenetic effects of adrenomedullin seemed to be 
mediated through the PI3K/Akt signalling pathway. 
- Adrenomedullin did not seem to influence the paracrine properties of EPCs, i.e release 
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